CL2022002379A1 - Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso. - Google Patents
Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso.Info
- Publication number
- CL2022002379A1 CL2022002379A1 CL2022002379A CL2022002379A CL2022002379A1 CL 2022002379 A1 CL2022002379 A1 CL 2022002379A1 CL 2022002379 A CL2022002379 A CL 2022002379A CL 2022002379 A CL2022002379 A CL 2022002379A CL 2022002379 A1 CL2022002379 A1 CL 2022002379A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- nucleic acid
- sin
- short interfering
- acid molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Abstract
MOLÉCULA DE ÁCIDO NUCLEICO INTERFERENTE CORTO (siNA); COMPOSICIÓN QUE LA COMPRENDE; Y SU USO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062986150P | 2020-03-06 | 2020-03-06 | |
US202063109196P | 2020-11-03 | 2020-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022002379A1 true CL2022002379A1 (es) | 2023-07-28 |
Family
ID=75278356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022002379A CL2022002379A1 (es) | 2020-03-06 | 2022-09-01 | Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso. |
Country Status (15)
Country | Link |
---|---|
US (4) | US20220364096A1 (es) |
EP (1) | EP4121533A1 (es) |
JP (1) | JP2023515664A (es) |
KR (1) | KR20220163960A (es) |
CN (1) | CN115485384A (es) |
AU (1) | AU2021230601A1 (es) |
BR (1) | BR112022017287A2 (es) |
CA (1) | CA3170466A1 (es) |
CL (1) | CL2022002379A1 (es) |
CO (1) | CO2022014258A2 (es) |
IL (1) | IL296045A (es) |
MX (1) | MX2022011012A (es) |
PE (1) | PE20221578A1 (es) |
TW (1) | TW202208625A (es) |
WO (1) | WO2021178885A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200270611A1 (en) * | 2017-09-14 | 2020-08-27 | Janssen Biopharma, Inc. | Galnac derivatives |
EP4121533A1 (en) * | 2020-03-06 | 2023-01-25 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
JP2023548031A (ja) | 2020-10-21 | 2023-11-15 | アリゴス セラピューティクス インコーポレイテッド | 二環式化合物 |
WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
US20230399645A1 (en) * | 2022-05-16 | 2023-12-14 | University Of Massachusetts | Optimized sirna scaffolds |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2173358B1 (en) * | 2007-06-22 | 2015-10-21 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
JP6005628B2 (ja) | 2010-04-28 | 2016-10-12 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾ヌクレオシド、その類似体、およびこれらから調製されるオリゴマー化合物 |
CA2833778C (en) * | 2011-06-30 | 2021-09-28 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
EA201490993A1 (ru) * | 2011-11-18 | 2014-09-30 | Элнилэм Фармасьютикалз, Инк. | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи |
US9611479B2 (en) * | 2014-02-18 | 2017-04-04 | Osaka University | Crosslinked nucleoside and nucleotide |
WO2017027350A2 (en) * | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
EP3506909B1 (en) | 2016-09-02 | 2022-06-29 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
KR20230115344A (ko) | 2016-09-02 | 2023-08-02 | 애로우헤드 파마슈티컬스 인코포레이티드 | 표적화 리간드 |
DK3607069T3 (da) * | 2017-04-05 | 2022-11-21 | Silence Therapeutics Gmbh | Produkter og sammensætninger |
WO2019105418A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
CA3117163A1 (en) | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
EP4121533A1 (en) * | 2020-03-06 | 2023-01-25 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
-
2021
- 2021-03-05 EP EP21715377.4A patent/EP4121533A1/en active Pending
- 2021-03-05 US US17/194,079 patent/US20220364096A1/en active Pending
- 2021-03-05 CN CN202180032666.3A patent/CN115485384A/zh active Pending
- 2021-03-05 TW TW110108015A patent/TW202208625A/zh unknown
- 2021-03-05 JP JP2022552538A patent/JP2023515664A/ja active Pending
- 2021-03-05 MX MX2022011012A patent/MX2022011012A/es unknown
- 2021-03-05 BR BR112022017287A patent/BR112022017287A2/pt unknown
- 2021-03-05 IL IL296045A patent/IL296045A/en unknown
- 2021-03-05 CA CA3170466A patent/CA3170466A1/en active Pending
- 2021-03-05 KR KR1020227034100A patent/KR20220163960A/ko active Search and Examination
- 2021-03-05 WO PCT/US2021/021199 patent/WO2021178885A1/en unknown
- 2021-03-05 AU AU2021230601A patent/AU2021230601A1/en active Pending
- 2021-03-05 PE PE2022001900A patent/PE20221578A1/es unknown
-
2022
- 2022-02-15 US US17/672,268 patent/US11549110B2/en active Active
- 2022-09-01 CL CL2022002379A patent/CL2022002379A1/es unknown
- 2022-10-05 CO CONC2022/0014258A patent/CO2022014258A2/es unknown
- 2022-11-29 US US18/059,561 patent/US20230332153A1/en active Pending
-
2023
- 2023-07-28 US US18/361,363 patent/US20230365970A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4121533A1 (en) | 2023-01-25 |
AU2021230601A2 (en) | 2022-10-20 |
BR112022017287A2 (pt) | 2022-11-16 |
CN115485384A (zh) | 2022-12-16 |
PE20221578A1 (es) | 2022-10-06 |
US20230365970A1 (en) | 2023-11-16 |
MX2022011012A (es) | 2022-10-07 |
US20220177888A1 (en) | 2022-06-09 |
KR20220163960A (ko) | 2022-12-12 |
US20230332153A1 (en) | 2023-10-19 |
JP2023515664A (ja) | 2023-04-13 |
CA3170466A1 (en) | 2021-09-10 |
AU2021230601A1 (en) | 2022-10-06 |
US11549110B2 (en) | 2023-01-10 |
TW202208625A (zh) | 2022-03-01 |
CO2022014258A2 (es) | 2022-12-30 |
IL296045A (en) | 2022-10-01 |
US20220364096A1 (en) | 2022-11-17 |
WO2021178885A1 (en) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022002379A1 (es) | Molécula de ácido nucleico interferente corto (sina); composición que la comprende; y su uso. | |
CO2021009695A2 (es) | Conjugados de il-2 y métodos de uso de este | |
BR112022017986A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
EP4293126A3 (en) | Analysis of multiple analytes using a single assay | |
CL2020000937A1 (es) | Anticuerpo multiespecífico. | |
EA202090290A1 (ru) | ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР | |
CO2020010303A2 (es) | Conjugados de il-15, y sus usos | |
CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
ECSP099027A (es) | Anticuerpos anti-dll4 y métodos que los usan | |
ECSP088543A (es) | Anticuerpos anti-ox40l y métodos que los utilizan | |
BR112017012351A2 (pt) | compostos inibidores de bcl xl que têm permeabilidade celular baixa e conjugados de fármaco-anticorpo que incluem os mesmos | |
GT201000088A (es) | 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
BRPI0607323B8 (pt) | composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo | |
BR112017017142A2 (pt) | métodos e composições para redução de produtos de amplificação não específicos | |
CL2021002656A1 (es) | Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso. | |
BRPI0814343A2 (pt) | Materiais e métodos para a seleção da sexagem do esperma | |
BR112017013277A2 (pt) | composição aquosa, método de amplificação isotérmica de ácido nucleico e kit | |
BR112017022329A2 (pt) | métodos para detectar aglutinação e composições para uso na prática do mesmo | |
ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
BR112022012731A2 (pt) | Anticorpo anti-ox40 e uso do mesmo | |
CO2023014770A2 (es) | Degradadores de cdk2 y sus usos | |
BRPI0604502A (pt) | controles de ensino de metilação de gene | |
BR112022009244A2 (pt) | Complexo, composição, kit, uso de um complexo, substância antibiótica derivatizada, método para produzir uma substância antibiótica estabilizada e usos de um reagente de derivatização nucleofílica e de um antibiótico derivatizado | |
AR103576A1 (es) | Molécula sustrato |